Skip to content

Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes

Effect of Dietary Carbohydrate on Diabetes Control and Beta Cell Function in Children With Newly Diagnosed Diabetes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05899166
Enrollment
52
Registered
2023-06-12
Start date
2024-05-31
Completion date
2029-04-30
Last updated
2025-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Keywords

carbohydrate reduced, low-carb, diabetes, keto

Brief summary

The goal of this clinical trial is to test the effects of a ketogenic diet on the progression and control of type 1 diabetes in children with newly diagnosed diabetes. The main questions to answer are: * Does a ketogenic diet prolong the honeymoon period of type 1 diabetes? * Does a ketogenic diet improve diabetes control? * Is a ketogenic diet safe, acceptable and sustainable in children with newly diagnosed diabetes? * What are the microbiome, inflammatory and metabolic changes linking diet to β-cell function? Participants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education for 9 months. * Diabetes care devices will be connected for cloud-based data collection. * Bi-weekly data downloads and remote check-ins will assess dietary intake, satisfaction with diet and study procedures, and possible safety concerns. * During four study visits held at at baseline, 1, 5, and 9 months, an intravenous catheter (IV) will be placed for collection of 5 blood samples before and up to 2 hours after a liquid test meal (protein shake) to assess insulin response. A stool sample will also be collected to assess microbiome changes. * Children and their caregivers may be invited to participate in a semi-structured interview, and online questionnaires to assess their experience with the diet and diabetes care, general well-being and quality of life. * Children and their caregivers may be invited to participate in a follow-up visit to evaluate long-term effects after 24 months. Comparison will be made between a ketogenic vs standard diet.

Detailed description

Type I diabetes is caused by an autoimmune destruction of insulin producing β-cells in the pancreas, resulting in absolute insulin deficiency. In the first months after diagnosis, a small number of β-cells typically remain and, by producing insulin, significantly improve diabetes control and reduce disease burden. Preliminary data suggest that this early disease stage entitled the honeymoon period might be extended by a ketogenic diet, which would provide a major therapeutic advantage and may reduce chronic disease burden. To test the hypothesis that a ketogenic vs. standard diet will extend the honeymoon period and improve diabetes control in children, the researchers are conducting a study employing education and food deliveries of a ketogenic or standard diet to children and their families. Fifty-two children aged 5 to 12 years with newly diagnosed diabetes will participate. Children will be assigned by chance (randomized) to receive either a ketogenic or a standard diet for 9 months. Chances to be assigned to either diet are 50:50 like a coin flip, and 26 children will participate in each diet arm. Participants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education throughout the 9 months. Continuous glucose monitoring (CGM) and diaries will be used for cloud-based data collection. Bi-weekly data downloads and remote check-ins will be performed to assess dietary intake, satisfaction with diet and study procedures, and possible safety concerns. Participants are instructed to measure blood ketone levels with their home ketone meter anytime blood glucose levels exceed a safety threshold and to call the study physician for persistent low glucose levels or ketones above diet specific safety thresholds. Study visits are held at at baseline, 1, 5, and 9 months to collect height, weight, stool and blood samples for hormones, metabolites and inflammatory biomarkers. At each visit, an intravenous catheter (IV) will be placed to collect fasting blood samples, followed by a liquid test meal (protein shake) and collection of four additional blood samples from the IV over the course of two hours. Prior to each visit, participants will collect stool samples at home using provided kits. In addition, participants and their families may be invited to participate in a semi-structured interview, and online questionnaires to asses their food intake, experience with the diet, diabetes care burden and complications, and general well-being and quality of life. They may also be invited to participate in a follow-up visit to evaluate long-term effects after 24 months.

Interventions

OTHERKetogenic diet, food delivery and education

Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.

OTHERStandard diet, food delivery and education

Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.

Sponsors

University of South Florida
CollaboratorOTHER
Indiana University
CollaboratorOTHER
Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Children aged 5 to 12 years. * Within 3 month of diabetes diagnosis. * Insulin adjusted HbA1c ≤9 if enrolled ≥ 2 months pat diagnosis. * Type 1 diabetes confirmed by immediate insulin requirement and any 2 of the following criteria: autoimmunity marker \[glutamate decarboxylase-65, islet-antigen-2, zinc transporter-8, insulin \[prior to first insulin dose\]; age under 10 years, BMI \<95th percentile. * Family committed and able to participate in study education and implement dietary intervention.

Exclusion criteria

* Dietary needs or habits incompatible with the study meal plans, (e.g., vegan, major food intolerances/allergies, ketogenic). * Eating disorders as assessed by Chede-Q8. * Major medical illness or use of medications other than insulin that could interfere with metabolic or glycemic variables. * Major psychiatric illness.

Design outcomes

Primary

MeasureTime frameDescription
Decline in Beta-cell FunctionChange over 1, 5, and 9 months, corrected for baselineChange in C-peptide 2-h area under the curve after a mixed-meal tolerance test (ΔCP).

Secondary

MeasureTime frameDescription
Pediatric Quality of Life (PEDSQL) Diabetes Module - child1, 5, 9, and optional at 24 monthsValidated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.
Lipoprotein Subfractions1, 5, 9, and optional at 24 monthsFasting blood
Inflammasome, targeted1, 5, 9, and optional at 24 monthsInterleukins 1β, 17, 23, 6, 10; high sensitivity c-reactive protein; tumor necrosis factor α, interferon gamma
Microbiome, targeted and untargeted1, 5, 9, and optional at 24 monthsExtraction and sequencing will be performed by Qiagen PowerSoil DNA extraction using Qiagen's DNeasy 96 PowerSoil Pro QIAcube HT Kit (480), followed by whole genome sequencing (WGS) using a miniaturized version of the NEBNext Ultra FS II method.
Metabolome, targeted and untargeted1, 5, 9, and optional at 24 monthsBlood samples will be processed using liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR). The LC-MS analyses will be carried out on a Sciex triple quadrupole mass spectrometer couple to an Exion ultra-performance LC system. The targeted analysis will utilize the Biocrates Q500 targeted metabolomics assay which quantifies more than 500 metabolites over 26 chemical classes (Biocrates Inc., Innsbruck, Austria). Data processing to yield metabolite concentrations in micromolar units will utilize the Biocrates MetIDQ software. The NMR data will be acquired on a Bruker Avance NEO 700 MHz NMR equipped with a TCI cryoprobe and a SampleXPress automatic sample changer. The data will be processed using the Chenomx NMR Processor and Profiler packages (Chenomx, Edmonton, CA) to yield quantitative data in millimolar units.
Problem Areas in Diabetes (PAID-Ped) - child1, 5, 9, and optional at 24 monthsValidated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.
Problem Areas in Diabetes (PAID-PR) - parent1, 5, 9, and optional at 24 monthsValidated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.
Pediatric Quality of Life (PEDSQL) General Module - parent1, 5, 9, and optional at 24 monthsValidated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.
Pediatric Quality of Life (PEDSQL) General Module - child1, 5, 9, and optional at 24 monthsValidated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.
Pediatric Quality of Life (PEDSQL) Diabetes Module - parent1, 5, 9, and optional at 24 monthsValidated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.
Child Eating Disorder Examination Questionnaire (ChEDE-Q8)1, 5, 9, and optional at 24 monthsValidated questionnaire, scored according to published standards. Scores range 0-42, higher scores are worse.
Perceptions on Diet Management of Diabetes1, 5, 9, and optional at 24 monthsQuestionnaire to assess participants' and caregivers' perceptions of the influence of the diet on their diabetes management.
Qualitative patient perspectives, interview - parentoptional at 9 monthsInterviews will be held with children and caregivers separately after implementation and completion of the intervention.
Qualitative patient perspectives, interview - childoptional at 9 monthsInterviews will be held with children and caregivers separately after implementation and completion of the intervention.
Time in Range (TIR) 70-180 mg/dlOver 9 months and optional at 24 monthsFrom continuous glucose monitoring (CGM) - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time in very high Range (TIR) >250 mg/dlOver 9 months and optional at 24 monthsFrom CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Duration of Clinical Diabetes Remission1, 5, 9, and optional at 24 monthsCalculated based on percent children with insulin dose corrected HbA1c (IDAA1c) \<9.
Time in low Range (TIR) <70 mg/dlOver 9 months and optional at 24 monthsFrom CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time in very low Range (TIR) <55 mg/dlOver 9 months and optional at 24 monthsFrom CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time in high Range (TIR) >180 mg/dlOver 9 months and optional at 24 monthsFrom CGM - percent time spent in the specified glycemic target range will be computed throughout study participation 2-week increments.
Average Blood GlucoseOver 9 months and optional at 24 monthsFrom CGM - will be computed throughout study participation in 2-week increments.
Coefficient of Glycemic Variation (CV)Over 9 months and optional at 24 monthsFrom CGM - will be computed by dividing glucose standard deviation by glucose average throughout study participation in 2-week increments.
Mean Amplitude of Glycemic Excursions (MAGE)Over 9 months and optional at 24 monthsFrom CGM - will be computed using published formula throughout study participation in 2-week increments.
Total Daily Insulin DoseOver 9 months and optional at 24 monthsFrom insulin administration device uploads - will be computed in units per kg throughout study participation in 2-week increments.
HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)1, 5, 9, and optional at 24 monthsCalculated from fasting blood draw \[fasting insulin (µU/ml) × fasting plasma glucose (mg/dl)\]/405.
BMI1, 5, 9, and optional at 24 monthsWeight divided by height squared.
Lipid panel1, 5, 9, and optional at 24 monthsFasting blood - total, LDL and HDL cholesterol, and triglycerides.
HDL to Triglyceride Ratio1, 5, 9, and optional at 24 monthsFasting blood

Other

MeasureTime frameDescription
BOHB (beta-hydroxybutyrate), fasting blood concentrationOver 9 months and optional at 24 monthsObtained at daily increasing to weekly intervals as effect modifier of beta-cell function.
Growth1, 5, 9, and optional at 24 monthsSafety Measure - Height standard deviation score will be calculated from serial height measurements obtained during study visits using CDC age and sex specific references.
Growth velocity1, 5, 9, and optional at 24 monthsSafety Measure - Growth velocity will be calculated from serial height measurements obtained during study visits.
Weigh-gain1, 5, 9, and optional at 24 monthsSafety Measure - Weight SDS and gain will be calculated from serial weight measures obtained during study visits with calibrated scale.
Confirmed KetoacidosisOver 9 months and optional at 24 monthsSafety Measure - Defined by elevated BOHB, blood pH \<7.3 and serum bicarbonate \<15. Rates will be computed as total number of events divided by total patient years of follow-up.
Severe HypoglycemiaOver 9 months and optional at 24 monthsSafety Measure - Defined as blood glucose \< 55 mg/dl and requiring glucagon or resulting in seizure or coma. Rates will be computed as total number of events divided by total patient years of follow-up.
Diabetes Related Emergency VisitsOver 9 months and optional at 24 monthsSafety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.
Diabetes Related HospitalizationsOver 9 months and optional at 24 monthsSafety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.
Study termination for disordered eatingOver 9 monthsSafety Measure - ChEDE-Q8 diagnostic score with clinical confirmation. Total number of events.
Study termination for growth decelerationOver 9 monthsSafety Measure - Undesired weight loss or significant deceleration in longitudinal growth may warrant termination of study participation. Total number of events will be computed.
Study termination for dyslipidemiaOver 9 monthsSafety Measure - LDL \>200 mg/dl will trigger review of additional risk factors and may prompt diet modification to lower intake of saturated fats. If persistent, study participation may be terminated. Total number of events will be computed.
Time above tight Range (TIR) >140 mg/dlOver 9 months and optional at 24 monthsFrom CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time in tight Range (TIR) 70-140 mg/dlOver 9 months and optional at 24 monthsFrom CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.

Countries

United States

Contacts

Primary ContactBelinda Lennerz, MD PhD
belinda.lennerz@childrens.harvard.edu857-218-3896

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026